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Abstract
GRID directs alternating regions of high- and low-dose radiation at tumors. A large animal model mimicking the geometries of human treatments is needed to complement existing rodent systems (eg, microbeam) and clarify the physical
and biological attributes of GRID. A pilot study was undertaken in pet dogs with spontaneous soft tissue sarcomas to
characterize responses to GRID. Subjects were treated with either 20 Gy (3 dogs) or 25 Gy (3 dogs), delivered using 6
MV X-rays and a commercial GRID collimator. Acute toxicity and tumor responses were assessed 2, 4, and 6 weeks later.
Acute Radiation Therapy Oncology Group grade I skin toxicity was observed in 3 of the 6 dogs; none experienced a
measurable response, per Response Evaluation Criteria in Solid Tumors. Serum vascular endothelial growth factor, tumor
necrosis factor a, and secretory sphingomyelinase were assayed at baseline, 1, 4, 24, and 48 hours after treatment. There
was a trend toward platelet-corrected serum vascular endothelial growth factor concentration being lower 1 and 48 hours
after GRID than at baseline. There was a significant decrease in secretory sphingomyelinase activity 48 hours after 25 Gy
GRID (P ¼ .03). Serum tumor necrosis factor a was quantified measurable at baseline in 4 of the 6 dogs and decreased in
each of those subjects at all post-GRID time points. The new information generated by this study includes the observation
that high-dose, single fraction application of GRID does not induce measurable reduction in volume of canine soft tissue
sarcomas. In contrast to previously published data, these data suggest that GRID may be associated with at least shortterm reduction in serum concentration of vascular endothelial growth factor and serum activity of secretory sphingomyelinase. Because GRID can be applied safely, and these tumors can be subsequently surgically resected as part of
routine veterinary care, pet dogs with sarcomas are an appealing model for studying the radiobiologic responses to
spatially fractionated radiotherapy.
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Introduction
Spatially fractionated radiation therapy (SFRT) involves intentional direction of highly nonuniform radiation fluences toward
tumors. The first reports of SFRT describe passing orthovoltage X-ray beams through sieve-like collimators; orthovoltage
radiation is poorly penetrating, so the goal of this so-called
GRID therapy was to improve dose deposition in deep-seated
tumors, while maintaining acceptable normal tissue complication rates in superficial tissues (eg, skin).1-3 This approach
became obsolete with the advent of megavoltage radiation therapy, which is both deeply penetrant and naturally skin sparing.
There has, however, been a recent resurging interest in SFRT,
fueled in part by clinical reports of positive outcomes for the
management of bulky tumors in human patients with cancer
treated with a combination of megavoltage GRID therapy and
conventionally fractionated radiation therapy (RT).4-6 Preclinical research has also shown that impressive normal tissue sparing can be achieved through delivery of microbeam radiation, a
small-scale version of SFRT, as compared with confluent
(broad-beam) radiation.7-10 Finally, there are data suggesting
the potential for SFRT to advantageously alter the tumor
microenvironment, with regard to both immune and microvascular functions.11,12
Current clinical SFRT practice involves delivery of 10 to 20
Gy of GRID in a single fraction, followed by a course of conventionally fractionated radiation therapy. There have also
been reports of using advanced radiotherapy planning and
delivery techniques to create 3-dimensional SFRT that restricts
the high-dose regions to occurring within tumors, while sparing
surrounding normal tissues from unnecessary exposures; this
technique is often referred to as LATTICE.13-15 Regardless of
the technical implementation (GRID or LATTICE), it is
unclear why this approach of single fraction SFRT preceding
conventional conformal irradiation has yielded impressive
local tumor control in patients with bulky tumors, for which
there would be a limited prognosis with conventional radiation
therapy alone. It is also postulated that vascular, immunologic,
and bystander effects may contribute to the clinical success of
SFRT. Significant clinical- and laboratory-based efforts have
supported the role of the tumor microenvironment in SFRT.
For example, it has been shown that high-dose GRID results in
acute induction of tumor necrosis factor a (TNF-a), ceramide,
and secretory sphingomyelinase (S-SMase), which can be measured in serum of human patients with cancer and which

correlates strongly with the probability of a measurable tumor
response.16,17 Ceramide and S-SMase in particular have been
proposed to enhance the direct effects of radiation on the tumor
cells through their ability to induce apoptosis in the tumor
microvascular endothelial cells.18 In addition to these clinical
investigations, a substantial body of work exists, wherein
tumor and normal tissue responses to mini- and microbeam
irradiation in mice have been studied.7-9,12
There are, however, significant limitations to the use of
rodent models, largely related to the fact that the kilovoltage
X-ray mini- and microbeam geometries do not reflect the physical characteristics of clinically utilized megavoltage SFRT
approaches; these physical differences likely give rise to significant differences in biologic responses. A large animal
model system would aid in overcoming some of these limitations and complement the available animal models. We therefore propose studying responses to SFRT in pet dogs with
spontaneously occurring tumors. This model has the advantages of using SFRT beam geometries and tumor geometries,
which closely mirror those encountered in human cancer
clinics, as well as responses of tumors which can be studied
in the setting of a naturally developing host tumor microenvironment, inclusive of an intact immune system. Another potential advantage of the proposed pet dog model is the ability to
study the biologic effects of SFRT in tissue samples obtained
when surgical removal of the tumor (as part of standard clinical
management of veterinary patients) follows application of
SFRT. Furthermore, it may also be possible to expand the
utility of this pet dog “model” to allow the study of the shortand long-term impacts of SFRT in situ, if such treatment provides meaningful palliation for otherwise unresectable tumors.
Through this pilot study, we therefore sought to characterize
the clinical and biologic responses to high-dose, single fraction
GRID therapy in pet dogs with spontaneously occurring soft
tissue sarcomas (STS). We opted to focus on STS because these
are common in pet dogs, are usually superficial, and thus accessible for repeated tissue sampling, and display similar clinical
and biological features to the human condition. Canine STS are
common on extremities and the trunk. They locally invade soft
tissues. Metastasis does not occur frequently or early. Standard
treatment for low- and intermediate-grade STS involves wide
surgical excision. Postoperative, definitive-intent radiation
therapy (an example of a common protocol being 3 Gy fractions, delivered daily [Monday through Friday] for a total of 18
fractions) is recommended when histologic margins are narrow
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Materials and Methods
Animals
A total of 6 privately owned pet dogs with spontaneously
occurring STS were studied. Dogs were presented for evaluation at the College of Veterinary Medicine, North Carolina
State University. This study was approved by the University’s
Institutional Animal Care and Use Committee (protocol identification 13-151-O).
Dogs were eligible for enrollment in this prospective clinical
study if they had a histologically or cytologically confirmed STS
that was at least 6 cm in diameter. Subjects had to be free of
gross metastatic disease, as assessed by evaluation of the draining lymph node and thoracic radiography. Subjects also had to
be free of concurrent illness, which would preclude general
anesthesia. Subjects with ulcerated, or otherwise unhealthy, integument overlying the tumor were excluded. Study participation
was offered to pet owners in cases where standard therapy was
declined. Because the study was short in duration and focused on
local tumor effects, complete clinical staging was not required.
Because some dogs were enrolled with a cytologic diagnosis of
STS, tumor grade was not known in all cases. Signed informed
consent was obtained from all owners.

GRID Therapy Dosimetry
GRID radiation is delivered using a commercial GRID collimator (Dot Decimal Inc, Sanford, Florida) placed on a standard
linear accelerator (Novalis TX; Varian Medical Systems, Palo
Alto, California). GRID therapy dosimetry is generally characterized by dose underneath one of collimator openings at the
depth of Dmax (peak dose) and the dose between the adjacent
collimator openings (valley dose).30 The monitor unit (MU) per
dose is calculated by the prescribed treatment dose divided by a
GRID collimator factor. The GRID collimator factor is defined
as the ratio of the peak dose using the GRID collimator at a

GRID Factor vs. Field Size

0.95

GRID Factor (cGy/MU)

or incomplete.19 Adjuvant chemotherapy is only considered for
high-grade STS, where the metastatic rate is *40%. Radiotherapy can also be useful for the management of unresectable STS.
Measurable responses (tumor volume reduction) are experienced
by approximately 50% of patients, and the median progressionfree interval is 1 year, when full-course radiotherapy (eg, 3 Gy 
18 fractions) is employed.20,21 More commonly, hypofractionated radiotherapy is employed for the management of bulky
STS in dogs, which controls tumors for approximately 6
months.22,23 Recently, stereotactic body radiotherapy has been
used for the management of unresectable canine STS. Results of
early experiences have not yet been published, but in the experience of these authors, it is common to employ protocols such as
20 Gy  1 fraction or 10 Gy  3 fractions. Anecdotally,
response rates and duration are similar to that reported for fullcourse radiotherapy. Colleagues at our institution have used
canine STS as a comparative model for studying response to
heat and radiotherapy for many years.20,24-29
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Figure 1. Measured GRID factor as a function of treatment field size
(cm2) at isocenter (d ¼ Dmax) for 6 MV X-rays on a Novalis TX linear
accelerator using a brass GRID collimator. For a given field size
(in area) and GRID treatment dose, the monitor units are calculated
using the GRID factor curve, above. We have explored different
formats of GRID field factor as a function of treatment portal sizes,
including equivalent square field size, and total area of the field size
for a range of field sizes and shapes we anticipated to use for the GRID
therapy in dogs. We found that the GRID factor and field size in area
capture the most stable relationship, of all tested.

given field size and the dose under the accelerator output calibration condition, where 1 MU gives 1.0 cGy of dose. The
GRID factor is a function of field size and photon energy (6
and 10 MV) is measured using an ion chamber (PTW 30013
Waterproof Farmer Chamber; RD Inc, Albertville, Minnesota)
and Mapcheck QA device (Sun Nuclear Corp, Melbourne,
Florida). The measured field size range is from 5 cm  5 cm
to 25 cm  24 cm (maximum field size to be used with the
GRID collimator). Figure 1 shows the dose per MU dependence on beam energy and field size for GRID therapy. Twodimensional dose distribution at depth of Dmax is measured
using RTQA2 GAFchromic film (Ashland Inc, Covington,
Kentucky). Figures 2 and 3 show the GRID radiation beam
profile and the percentage depth dose along the central axis
of the beam, respectively.

Treatment Planning and Irradiation
All subjects underwent general anesthesia for radiation therapy
simulation using computed tomography (CT) and again 1 to 3
days later for GRID therapy. Computed tomography images
were obtained before and after intravenous (IV) administration
of an iodinated contrast medium (159.1 mg/kg iohexol, Omnipaque 350; GE Healthcare, Princeton, New Jersey). Organs at
risk and targets were contoured on the simulation CT using a
commercial treatment planning system (Eclipse version 11.0;
Varian Medical Systems, Palo Alto, California). The planning
target volume (PTV) was defined by a 1-cm isotropic expansion applied to the gross tumor volume. A single fraction of
either 20 or 25 Gy was prescribed to a depth of 1.5 cm (Dmax)
and delivered through the GRID collimator. A single field, at
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of Physicists in Medicine, Task Group Report 142 (AAPM
TG-142).
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Figure 2. A 6-MV GRID field (25 cm  24 cm) beam profile. The
dose profile is measured at Dmax using Gafchromic RTQA-2 film. The
film density is converted to dose using a film density calibration curve
based on ion chamber data in conventional (non-GRID) fields.

Subjects were evaluated for radiation toxicity during recheck
examination performed 2, 4, and 6 weeks after GRID irradiation, using Radiation Therapy Oncology Group (RTOG) acute
radiation morbidity scoring criteria.31 There is a published and
peer-reviewed veterinary RTOG acute radiation morbidity
scoring scheme.32 However, this veterinary scheme is limited
by lack of separation between what the RTOG classifies as
grade 3 versus 4 toxicity and therefore is not directly translatable toxicity scoring in human trials. Therefore, to maximize
translational potential, we directly applied the RTOG criteria to
dogs, without modification. Tumor responses were also quantified via Response Evaluation Criteria in Solid Tumors
(RECIST) at those visits.33
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Figure 3. Percentage depth dose (PDD) of the 6-MV photon 15 cm 
15 cm GRID filed, through the central opening of the GRID collimator. The GRID factor is defined as the ratio of dose at Dmax of a
GRID field of given size and dose at Dmax of a 10  10 cm field under
machine output calibration condition, times the machine output factor
of 1 cGy/MU. We determined the relative dose ratio by measuring the
dose on the central diode detector of a MapCHECK array system from
a given GRID field radiation and a 10  10 cm field radiation under
the same setup (100 cm SSD, central axis, with no additional build-up).
We assumed that the depth difference between 6 MV Dmax (1.5 cm) and
the measurement depth (2 cm) has negligible effect on the relative
GRID factor measurement. SSD ¼ Source to surface distance.

100 cm source-to-surface distance, was used and shaped to
shield tissues outside the PTV using a multileaf collimator.
No bolus was used. The MU calculation was computed based
on the prescription dose and the GRID collimator factor for the
chosen beam energy and field size. In all cases, treatment was
delivered using a 6 MV X-ray beam. Monitor unit calculations
were performed manually by the prescribing radiation oncologist and independently verified by a medical physicist. Appropriate patient and tumor positioning were verified immediately
prior to treatment delivery, using kilovoltage cone-beam CT.
The linear accelerator is designated for veterinary and research
use only; the output calibration is performed based on the
methodologies of AAPM TG-51; daily, monthly, and annual
quality assurance testing is performed per American Association

Serum and plasma were obtained prior to and 1, 4, 24, and 48
hours after GRID irradiation; aliquots of each were stored at
80 C. The S-SMase activity was measured using C6-NBDSM as a substrate in serum samples. The standardized assay
contained 0.5 mL serum, 20 mM NBD-SM, 0.1 mM ZnCl2, and
0.1 M sodium acetate buffer (pH 5.0) in a final volume of 20
mL. Control assays contained 5 mM of EDTA instead of the
ZnCl2. Preliminary analyses determined the range of linearity
of the assay with respect to the volume of serum used as an
enzyme source. Reactions were allowed to continue for 3 hours
at 37 C and were stopped by the addition of 0.5 mL methanol.
After further incubation at 37 C for 30 minutes, the samples
were centrifuged at 1000g and the generation of fluorescent
product, NBD-ceramide was monitored by a reverse-phase
high-pressure liquid chromatograph using methanol:water:phosphoric acid (850:150:0.15, by volume) as a mobile phase.34
External standards were used to calculate the quantum yield of
the NBD-SM and its product, NBD-ceramide. Specific activity
was calculated as the difference in the activity measured in the
presence of Zn2þ and EDTA and presented as nmol/mL/h.
Materials for this assay included N-(6-((7-nitro-2-1,3-benzoxadiazol-4-yl)amino)hexanoyl)-D-erythro-sphingosine (C6NBD-Cer) and N-(6-((7-nitro-2-1,3-benzoxadiazol-4-yl)amino)hexanoyl)-sphingosine-1-pho sphocholine (C6-NBD-sphingomyelin) from Molecular Probes Inc (Eugene, Oregon).
Tumor necrosis factor a and vascular endothelial growth factor
(VEGF) were quantified in serum using commercial assays
(Canine TNF-a and VEGF Quantikine ELISA kits; R&D Systems, Inc, Minneapolis, Minnesota). Serum VEGF concentrations
were corrected for platelet concentration.

Statistical Analysis
Temporal changes in analyte concentrations were compared
using Friedman nonparametric test for repeated measures. All
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Table 1. Patient Demographics and Pretreatment Description of Tumors.
Subject ID Signalment

Body
Weight

Tumor Type

1
2
3
4
5
6

4.85 kg
30.4 kg
28.7 kg
23.6 kg
18.5 kg
29.9 kg

Soft tissue sarcoma,
Soft tissue sarcoma,
Chondrosarcoma
Soft tissue sarcoma,
Soft tissue sarcoma,
Soft tissue sarcoma,

Castrated male, Maltese
Castrated male, Chow Chow
Spayed female, Labrador retriever
Spayed female, mixed breed
Castrated male, American Eskimo
Castrated male, American Staffordshire
terrier

Maximum Tumor
Diameter
grade III
grade III
grade I
grade III
grade I

7.5 cm
9.8 cm
21 cm
22 cm
11 cm
7.5 cm

Tumor Location
Left antebrachium
Left caudal thigh
Left lateral thorax
Left lateral thorax
Right cranial thigh
Left elbow

Figure 4. Example of a GRID treatment plan for the same dog that is shown in Figure 5. Dose is depicted via relative isodose lines on a
parasagittal image (left: correlating with the beams-eye view) and an axial image (right) wherein the blue arrow indicates the beam’s axis; the
tumor is located on the cuadolateral thigh, and anatomic orientation is provided (eg, caudal, distal). The gross tumor volume is outlined in red.

statistical tests were performed using commercial software
(Prism version 6; GraphPad Software, Inc, La Jolla,
California).

Table 2. Treatment Descriptions and Oncologic Outcomes (Toxicity
and Response).

Results

1
2
3
4
5
6

Single fraction GRID therapy appears safe but does not result
in a measurable tumor response in dogs with macroscopic STS.
Six dogs were enrolled and treated with GRID alone, at 20 Gy
(3 dogs) and 25 Gy (3 dogs). All subjects were 11 years old at
the time of enrollment; other patient demographics data and
pre-treatment tumor characteristics are summarized in Table 1.
Based on tumor location and beam orientation for GRID treatments, skin was an important organ at risk to consider in evaluating for acute radiation toxicity. Aside from partial lung
irradiation (*15% of total lung volume) in 2 subjects, exposure of visceral organs within the thoracic and abdominal cavities was completely avoidable. Figure 4 is an example of a
GRID treatment plan for a canine sarcoma, demonstrating how
the radiation dose maps onto the tumor volume. Clinically,
dose calculation was performed via manual calculation of
MUs, as described; this figure was a simulation generated using
actual CT data from an enrolled subject (subject 2) and the
University of North Carolina’s in-house treatment planning
system, PLUNC.

Subject GRID Dose
Maximum RTOG Objective Response 6
ID
(Gy)
Acute Toxicity Score Weeks Post-GRID
20
20
20
25
25
25

0
1
0
0
1
1

Progressive disease
Stable disease
Not evaluable
Stable disease
Stable disease
Stable disease

Abbreviation: RTOG, Radiation Therapy Oncology Group.

Oncologic outcomes are summarized in Table 2. Briefly, 1
dog (subject 1) had its tumor surgically excised, 5 weeks postGRID (20 Gy) due to progressive local tumor growth. Histopathology of the tumor confirmed a high-grade STS, with
marked cortical and paracortical hyperplasia, but no evidence
of metastasis in the draining lymph node. Surgical margins
were free of neoplastic cells (wide margins); there were large
areas of necrosis and inflammatory infiltrates (histiocytes,
lymphocytes, and plasma cells), which are common in highgrade STS, but no specific pathologic changes that were attributable to GRID irradiation. Another dog (subject 3) was
euthanized 3 weeks post-GRID (20 Gy) due to persistent and
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Figure 6. Platelet-corrected concentration of vascular endothelial
growth factor (VEGF) as a function of time after irradiation, depicted
using a box and whisker plot.
Figure 5. Photograph of grade I skin toxicity (focal alopecia on the
lateral aspect of the thigh, where the GRID collimated radiation exited
the body).

poorly controlled tumor-associated pain. Autopsy was performed, and histopathologic evaluation of the tumor confirmed the mass to be a chondrosarcoma. There were
regions of hemorrhage, necrosis, and neutrophilic inflammation, but again, no changes that the attending board-certified
veterinary pathologists at our institution could attribute specifically to GRID irradiation. The remaining 4 dogs had stable
disease (per RECIST) 6 weeks post-GRID. Acute RTOG
grade I skin toxicity was observed in 3 of the 6 dogs, with 2
of those 3 having received 25 Gy. This included focal alopecia
and hyperpigmentation (Figure 5). Subject 2 was euthanized 9
months after GRID, due to progressive weakness, lethargy,
tumor-associated pain, and increased respiratory effort.
Autopsy confirmed a high-grade STS with pulmonary metastasis. The primary tumor was composed predominately of
necrotic tissue, with only a few regions of intact neoplastic
cells captured in histologic section. Again, no changes were
clearly associated with GRID irradiation; necrosis and inflammation are both characteristic of canine STS. Subject 4 was
euthanized by the primary care veterinarian due to poor quality of life, 1 year after GRID irradiation. Autopsy was not
pursued, and no description of the tumor was provided. Subject 5 was euthanized 3 months after GRID irradiation by the
primary care veterinarian. The tumor had become ulcerated
since the end of the study period; autopsy was not pursued.
Subject 6 was alive at the time of manuscript preparation; the
tumor remains intact but has reportedly progressively grown
since the end of the study period (per the family).
Similar to human tumors treated with GRID, in the
absence of measurable reduction in tumor size, there is no
spike in S-SMase activity. Serum biomarkers (VEGF and
TNF- a) were quantified in all 6 dogs, immediately before
GRID therapy and 1, 4, 24, and 48 hours later; due to a labhandling error, S-SMase activity was assayed in only 5 of
the 6 dogs (2 that were treated with 20 Gy and 3 that were
treated with 25 Gy). With such a small study size, and

Figure 7. Secretory sphingomyelinase (S-SMase) activity as a function of time after irradiation; error bars depict the standard deviation of
the mean.
Table 3. Serum Concentration of Tumor Necrosis Factor a (pg/mL),
as a Function of Time After Irradiation.
GRID
Dose
20 Gy

25 Gy

TNF-a (pg/mL)
Subject
ID
Pre-GRID 1 hour 4 hours 24 hours 48 hours
1
2
3
4
5
6

0.38
0
0
2.42
1.71
0.8

0
0
0
0
0.08
0

0
0
0
0
0
0

0
0
0
0
0
0

0
0
0
0
0
0

Abbreviation: TNF, tumor necrosis factor.

without appropriate control populations, it is difficult to
ascribe significant meaning to results of statistical tests.
Therefore, a combination of statistical results and qualitative descriptions of data is provided. Data are summarized
in Figures 6, 7, and Table 3.
Although not meeting statistical significance (P < .05) in a
Friedman test, the platelet-corrected VEGF concentration
decreased below baseline in 5 of the 6 subjects, 1 and 48 hours
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after GRID irradiation, suggesting a trend toward a treatmentinduced decline in VEGF.
The only statistically significant change was a decrease in SSMase activity 48 hours after 25 Gy GRID (P ¼ .03 in a Friedman test). The S-SMase activity decreased from baseline in 4
of 5 subjects, at 1 hour post-GRID. Values returned to, or were
higher than, baseline in 3 subjects by the 24-hour time point. To
aid in interpretation of S-SMase assay results, TNF-a was also
quantified in serum and was measurable at baseline in 4 of the 6
dogs and decreased (or was below the lower detection limit) in
each of those subjects at all post-GRID time points.

Discussion
This work documents that these GRID therapy protocols are
generally well tolerated with regard to acute radiation toxicity
in dogs and that GRID therapy alone is of no apparent use in
palliating canine patients with STS. GRID has biologic activity
similar to that experienced by human patients with cancer, in
that GRID monotherapy does not induce measurable tumor
shrinkage. Our study suggests that GRID treatment may modulate canine tumor vasculature, as indicated by apparent
changes in serum concentrations of VEGF. Thus, results of this
study demonstrate the feasibility of clinical implementation of
a GRID therapy program in a veterinary radiation oncology
clinic for the purposes of performing comparative oncology
research. Furthermore, although the study period ended 6
weeks after GRID irradiation, surgical and/or postmortem histopathologic descriptions of the tumors were available for half
of the enrolled subjects. Although this was a small study, it
does demonstrate that the ability to successfully acquire
autopsy data for a relatively high proportion of enrolled subjects is a strength of canine comparative oncology studies.
This study was exploratory in nature and was limited by
small sample size and lack of a control population (either unirradiated negative controls or positive controls having received
conformal RT). Despite these limitations, the data indicate that
the pet dogs with spontaneously arising tumors may be a good
model for translational research of SFRT. We observed that
there was no temporal rise in S-SMase activity in these dogs
that did not respond to GRID therapy. This is similar to what
has previously been reported in humans, when bulky tumors
are treated with GRID, wherein a rise in S-SMase coincided
with tumor shrinkage, but ceramide and S-SMase activity was
unchanged in patients whose tumors did not shrink.17 This
observation must be made with caution, though, because we
do not know if a GRID-responsive canine tumor would have
the same S-SMase response as is seen in humans, as none of the
dogs in this study had a measurable tumor volume reduction
after GRID irradiation. Furthermore, because there are no
known reports of single fraction GRID irradiation (without
additional chemoradiotherapy) for human sarcomas, we cannot
comment as to whether the lack of measurable volume reduction in canine STS is consistent with the clinical outcome
expected in people.
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Similar to what has been described in serum samples from
human patients with cancer before GRID irradiation, the dogs
in this series had highly variable basal levels of S-SMase activity. This may be due to variations in interindividual differences
in low-density lipoprotein content (not quantified) and/or presence of systemic inflammation before treatment.17 It is difficult
to explain the apparent decrease in S-SMase activity in the
hours after GRID. It is possible that the radiation kills many
endothelial cells and macrophages (these 2 cell types are the
main source of the secretory SMase) and we see a drop simply
because there are far fewer cells that produce it (even though
secretion per cell might be stimulated). It is interesting that at
20 Gy (but not at 25 Gy), S-SMase activity start increasing after
24 hours, which might be due to the fact that radiation damage
at 20 Gy was less pronounced than at 25 Gy, and thus stimulation may be observed after recovery of the macrophage/
endothelial population. It was also hypothesized, since the
activity is normalized per milliliter of sample, that the SSMase activity could be artificially decreased due to dilution
of blood during radiotherapy. In fact, dogs do receive IV fluid
therapy during irradiation. That said, the total volume of IV
fluids administered represented as a percentage of total estimated blood volume ranged from 3.1% to 7.7%, administered
over 45 to 90 minutes. This does not seem like a large enough
dilution to account for the activity changes observed in individual dogs. Finally, secretion of S-SMase in response to GRID
is likely mediated by TNF-a, so an observed initial decrease in
canine S-SMase activity might reflect slower TNF-a secretion
in dogs than humans. The fact that TNF-a was measurable in
some dogs before GRID, but became unmeasurable (results
below the detection limit) after GRID, is an interesting trend
that might account for the initial observed drop in sphingomyelinase activity, though confirmatory studies would certainly be
needed to support that hypothesis. Ionizing radiation is known
to induce the expression of TNF-a, which is a proinflammatory cytokine. In human patients treated with GRID,
measurable increases in serum concentrations of this cytokine
are common in tumors for which a complete clinical response is
noted, but serum levels remain stable, or even decrease, in
patients who do not experience a measurable response. Therefore, the lack of TNF-a induction in our canine population is
not surprising, and the decrease is not unprecedented. In fact,
the failure to induce this cytokine could possibly explain the
lack of observable clinical response. Another possibility is that
because TNF-a is relatively difficult to detect at low concentrations, the local change was not strong enough to result in a
measurable increase in serum concentrations.16
The potential that the observed changes in VEGF and SSMase could be related to anesthesia should not be overlooked.
Without a control group that received anesthesia alone, this
study can make no conclusions in that regard. It should also
be noted that this pilot study was designed with consideration
of previously published data, wherein Sathishkumar and colleagues measured serum SMase activity and ceramide concentration before treatment and 24, 48, and 72 hours after GRID
irradiation.17 In this study, we omitted the 72-hour time point
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but added 2 earlier points (1 and 4 hours). This was based on
preclinical data suggesting that radiation-induced ceramidemediated vascular endothelial apoptosis occurs within hours
of radiation exposure.35 Future studies to clarify our findings
should include more measurement time points.
In summary, the new information generated by this study
includes the observation that high-dose, single fraction application of GRID does not induce measurable reduction in volume of canine STS. Furthermore, and in contrast to previously
published data, there was a trend toward short-term reduction
in serum concentration of VEGF and serum activity of SSmase. These observations should be verified, and the cause
should be investigated. Because GRID can be applied safely,
and because these tumors can be subsequently surgically
resected as a component of routine veterinary care, pet dogs
with sarcomas are an appealing model for studying the radiobiologic responses to SFRT.
Because any number of imaging and physiology assays
could be performed in vivo before and after GRID application,
and because the resected tumor would provide large volumes
of tissue to evaluate any number of biological changes
(eg, immune cell infiltrates, neoangiogenesis, phenotypic
changes in cells within and outside the GRID pattern, etc), this
“model” system should prove useful for investigators interested
in studying more clinically relevant radiobiological effects of
SFRT that cannot be easily or realistically recapitulated in
existing rodent models or using existing mini- and microbeam
technologies.
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